GSK plc (GSK)
| Market Cap | 104.44B +36.0% |
| Revenue (ttm) | 44.05B +5.0% |
| Net Income | 6.40B +40.8% |
| EPS | 3.13 +42.6% |
| Shares Out | 4.01B |
| PE Ratio | 16.33 |
| Forward PE | 10.30 |
| Dividend | $1.77 (3.39%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | 3,136,165 |
| Open | 51.53 |
| Previous Close | 52.96 |
| Day's Range | 51.47 - 52.20 |
| 52-Week Range | 37.71 - 61.70 |
| Beta | 0.30 |
| Analysts | Hold |
| Price Target | 58.08 (+11.35%) |
| Earnings Date | Jul 28, 2026 |
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial numbers in GBP Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for GSK stock is "Hold." The 12-month stock price target is $58.08, which is an increase of 11.35% from the latest price.
News
GSK India first-quarter profit rises on steady vaccine demand
Vaccine maker GlaxoSmithKline Pharmaceuticals reported a 15.7% rise in first-quarter profit on Monday, aided by stable demand across its vaccine and drug portfolio, including respiratory and special...
GSK Looks 14.7% Overvalued on GF Value⢠as Dividend Sustainability Remains Key
GSK Looks 14.7% Overvalued on GF Value⢠as Dividend Sustainability Remains Key
GSK closer to relaunching Brexafemme, says Brookline
Brookline notes that the FDA’s daily drug safety related labeling changes includes changes to Brexafemme’s label, which the firm calls “concrete evidence” that GSK (GSK) is closer to relaunching Brexa...
Weekly Buzz:CIPLA, VTRS Win FDA Nod; BSX Cuts Jobs; ARGX Snaps Up FBRX; JNJ, GSK Strike Deals
(RTTNews) - The healthcare sector delivered another eventful week, marked by major regulatory approvals, strategic partnerships, acquisitions, restructuring initiatives and significant clinical trial ...
Drugmakers, retailers must face 'maximum strength' claim in decongestant false ad litigation in US
A federal appeals court on Thursday revived portions of nationwide litigation in which consumers accused drugmakers such as Procter & Gamble and retailers such as CVS of selling billions of dollars o...
GSK price target raised to 2,000 GBp from 1,950 GBp at Deutsche Bank
Deutsche Bank raised the firm’s price target on GSK (GSK) to 2,000 GBp from 1,950 GBp and keeps a Hold rating on the shares.
GSK Strikes $100M AI Deal With Relation Therapeutics To Boost Early Pipeline
(RTTNews) - GSK plc (GSK) announced a strategic collaboration with UK-based Relation Therapeutics to apply artificial intelligence in drug discovery and strengthen its early-stage pipeline.
GSK, Relation Therapeutics sign up to $110 million AI drug discovery deal
British biotech firm Relation Therapeutics said on Wednesday it had entered into a research collaboration with GSK worth up to $110 million to generate human cellular datasets and train AI models ...
GSK Looks 19.3% Overvalued on GF Value⢠as Dividend Sustainability Faces Mixed Signals
GSK Looks 19.3% Overvalued on GF Value⢠as Dividend Sustainability Faces Mixed Signals
Cabenuva demonstrates superiority to daily oral therapy in adolescents with HIV
GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK with Shionogi as a shareholder, announced data to be presented this week at the 26th…
GSK PLC (GSK) Shares Surge 3.3% -- What GF Score of 69 Tells Investors
GSK PLC (GSK) Shares Surge 3.3% -- What GF Score of 69 Tells Investors
GSK set to slash billions in costs over next three years by embracing AI sparking fears of a jobs bloodbath
GSK, led by boss Luke Miels, pictured, said it will be closing down its R&D site in Stevenage, Hertfordshire, and moving its staff to a new facility in Cambridge.
FTSE 100 Advances as Unilever and GSK Results Lift mood
Strong earnings boosted London shares as investors assessed banking results and global technology concerns. The post FTSE 100 Advances as Unilever and GSK Results Lift mood appeared first on Investoma...
GSK Q2 Earnings Call Highlights
GSK NYSE: GSK reported second-quarter sales growth of 5% at constant exchange rates to more than £8.4 billion, supported by Specialty Medicines and Vaccines, while outlining a new cost-savings and inv...
GSK Q2 Earnings Call Highlights
MarketBeat Week in Review – 06/08 - 06/12GSK (NYSE:GSK) reported second-quarter sales growth of 5% at constant exchange rates to more than £8.4 billion, supported by Specialty Medicines and Vaccines, ...
GSK heads to Cambridge with long-awaited positive vibes | Nils Pratley
Pharmaceutical company’s move to new £400m research centre accompanied by encouraging news for shareholders “A vote of confidence in British business,” trumpeted Andy Burnham, seizing the political gi...
Earnings tonic boosts FTSE 100 as oil falls back
Well-received earnings from Unilever, Croda and GSK spurred gains on the blue-chip FTSE 100.
GSK To Invest £400M In New Flagship R&D Centre In Cambridge, UK
(RTTNews) - GSK plc (GSK) announced plans to build a new global R&D centre on the Cambridge Biomedical Campus, reinforcing its commitment to UK life sciences with a £400 million investment over three ...
GSK Stock Rises as $2.52 Billion Savings Plan Funds Pipeline
GSK Stock Rises as $2.52 Billion Savings Plan Funds Pipeline
GSK Looks 17.2% Overvalued on GF Value⢠as Dividend Sustainability Remains Key
GSK Looks 17.2% Overvalued on GF Value⢠as Dividend Sustainability Remains Key
GSK Looks 17.2% Overvalued on GF Value⢠as Dividend Sustainability Faces Strategic Test
GSK Looks 17.2% Overvalued on GF Value⢠as Dividend Sustainability Faces Strategic Test
GSK to cut jobs amid £1.9bn cost-cutting plan and bid for faster drug development
Pharmaceuticals company is investing £400m in UK life sciences and moving scientists to new Cambridge R&D site Business live – latest updates The British drugmaker GSK is to announce sweeping job cuts...
GSK plc Earnings Call Transcript: Q2 2026
Q2 saw 5% sales growth and strong cash generation, led by specialty medicines and vaccines. The Accelerate Growth program targets £1.9B in annual savings to fund R&D and protect margins through key LOE periods, while the Nuvalent acquisition expands the oncology pipeline.
GSK plc Quarterly report: Q2 2026
GSK plc has published its Q2 2026 quarterly earnings report on July 28, 2026.
GSK plc Slides: Q2 2026
GSK plc has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 28, 2026.